Department of Obstetrics and Gynecology, San Martino Hospital and National Institute for Cancer Research, University of Genoa, Genoa, Italy.
Ann N Y Acad Sci. 2014 May;1317:17-23. doi: 10.1111/nyas.12411. Epub 2014 Apr 16.
Endometriosis is an estrogen-dependent inflammatory disease defined by the growth of endometrial stroma and glands outside of the uterus. Epidemiological and clinical studies show that estrogen is essential for the growth of endometriosis. There are several molecular links between estrogen production and inflammation in endometriosis. The enzyme aromatase P450 is expressed aberrantly in endometriosis and is stimulated by prostaglandin E2 , resulting in production of estrogen that induces prostaglandin E2 expression within endometriotic lesions. Furthermore, estrogen promotes the secretion of several inflammatory cytokines and growth factors, which contribute to the progression of endometriosis and stimulate estrogen production. On the basis of the local estrogen biosynthesis in endometriotic implants, nonsteroidal aromatase inhibitors have been successfully used to treat pain symptoms caused by endometriosis. These agents do not cause the disappearance of endometriosis; they cannot be considered routine treatment and should only be administered in adequately controlled clinical studies.
子宫内膜异位症是一种雌激素依赖性炎症性疾病,其特征是子宫内膜基质和腺体在子宫外生长。流行病学和临床研究表明,雌激素对于子宫内膜异位症的生长是必需的。在子宫内膜异位症中,雌激素的产生和炎症之间存在着几种分子联系。芳香酶 P450 酶在子宫内膜异位症中异常表达,并受前列腺素 E2 的刺激,导致产生雌激素,进而在内异症病变中诱导前列腺素 E2 的表达。此外,雌激素促进几种炎症细胞因子和生长因子的分泌,这有助于子宫内膜异位症的进展,并刺激雌激素的产生。基于子宫内膜异位症种植体中的局部雌激素生物合成,非甾体芳香酶抑制剂已成功用于治疗子宫内膜异位症引起的疼痛症状。这些药物并不能使子宫内膜异位症消失;它们不能被视为常规治疗方法,只能在充分控制的临床研究中使用。